Introduction {#s1}
============

Non-small cell lung cancer (NSCLC) is a very common carcinoma, accounting for 80%--85% of lung cancer cases, and also the leading cause of cancer-related deaths worldwide. ([@B22]; [@B29]). The management of treatment for NSCLC could be optimized by using pharmacogenetic testing ([@B10]). Numerous studies have showed that aberrant epidermal growth factor receptor (EGFR) pathway is a driving gene of NSCLC cancerogenesis, playing a considerable role in the process of malignancies, such as cell proliferation, differentiation and migration ([@B6]; [@B3]). It was reported that the EGFR tyrosine kinase inhibitors (TKIs) were effective in patients with EGFR sensitive mutations ([@B25]; [@B24]).

Erlotinib is an orally administered, reversible TKI indicated as first-line treatment for advanced NSCLC in patients with activating EGFR mutations and as second- and third-line treatment in patients with EGFR wild-type NSCLC ([@B37]). The most common activating mutations in EGFR are the exon 19 deletion and the exon 21-point mutation L858R ([@B38]). Compared with standard platinum doublet therapy, erlotinib showed dramatically improved the long-term survival rate and clinical response of EGFR sensitive mutation NSCLC. Despite of its striking efficacy, however, real-world clinical evidence demonstrated considerable individual variability in both therapeutic efficacy and toxicity ([@B32]; [@B9]). Suboptimal response and response failure to the treatment are also observed in clinical treatment. In addition, most of the patients experienced drug-related adverse events (such as skin rash and diarrhea) with fixed dose of erlotinib during their treatment course ([@B7]).

Research in advanced NSCLC has since focused on finding biological predictors of response and adverse events allowing for treatment optimization. More evidences showed that inter-patient variability in drug response and adverse events which reflect the systemic levels or intracellular concentrations of the drug ([@B5]). Absorption, distribution, and metabolism are important pharmacokinetics parameters for a drug, which are all significantly associated with the exposure level. Statistical correlations between these pharmacokinetic parameters and treatment outcomes and adverse events were observed. Thus, inter-individual variations in erlotinib pharmacokinetics may present important clinical consequences.

Increasing body of evidences recognized that genetic polymorphisms of drug-metabolizing enzymes and transporters may significantly influence the inter-individual variations in drug reaction and disposition ([@B8]). As an orally administrated small molecule TKI, erlotinib is mainly metabolized in the liver by cytochrome P450 CYP1A1, 1A2, 3A4, 3A5, and 2D6. Activities of these drug-metabolizing enzymes determine pharmacokinetics of the agents and therefore influence adverse events and therapeutic response rates. Nie et al. have reported that the polymorphism of CYP1A1 is a predictor for clinical outcome in NSCLC patients treated with EGFR-TKI therapy ([@B28]). Guillen et al. have also reported that determination of CYP3A4 and CYP1A2 phenotyping in plasma and dried blood spots could predict the pharmacokinetics and toxicity of erlotinib in NSCLC patients ([@B30]). ATP binding cassette subfamily B member 1 (ABCB1) and ATP binding cassette subfamily G member 2 (ABCG2) are important transporter of several drugs, the expression of which appear to affect the pharmacokinetics of erlotinib ([@B35]; [@B23]; [@B19]). Hamada et al. have reported that ABCB1 1236TT--2677TT--3435TT genotype is associated with higher plasma concentration and the risk of higher toxicity in patients treated with erlotinib ([@B10]). Neul et al. have reported that transporter genetic variants are promising novel factors to explain inter-individual variability in the response to TKI therapy ([@B26]). Chihiro et al. have also reported that the ABCB1 genotype is a potential predictor for erlotinib adverse events ([@B7]). Although the relationship between SNPs and treatment outcomes and toxicities were widely investigated, the results were inconsistent and none of those analyses clearly explains the determinants of the large inter-individual variability in the treatment outcomes and toxicity of erlotinib treatment.

Accordingly, genetic polymorphisms of the metabolizing enzymes and transporters could affect the expression of corresponding proteins, thus, may predict differences in erlotinib response and their adverse events. To validate this hypothesis, we determined to measure the steady state trough concentration of erlotinb, and analyzed the SNPs in metabolizing enzymes (P450) and transporters (ABC) in NSCLC patients treated with fixed dose erlotinib. We also investigated the correlations between the polymorphisms of these genes with the treatment outcomes and toxicities, respectively.

Patients and Methods {#s2}
====================

Patients and Study Design {#s2_1}
-------------------------

The study was carried out at Hunan Cancer Hospital, Hunan, China, between April 2016 and October 2018. Patients with advanced NSCLC who were treated with oral erlotinib at a standard dose of 150 mg were enrolled in our study. Inclusion criteria were as follows: 1) histologically confirmed NSCLC with EGFR sensitive mutation; 2) unmodified dosage of erlotinib during the treatment period. This study was designed and implemented by following the guidelines dictated in the Declaration of Helsinki. Ethics approval was obtained from the Independent Ethics Committee of Hunan Cancer Hospital and all patients were provided written informed consent.

Erlotinib Trough Plasma Concentration Determination {#s2_2}
---------------------------------------------------

Blood samples were collected 24 ± 3 h after the last drug administration but before the next administration at day 26-30 after the first dose of erlotinib, which aimed to ensure that the blood samples were steady state trough concentration samples. Blood samples (3 ml each) were collected into EDTA polypropylene tubes, centrifuged at 3000 r/min for 5 min. The remaining samples were prepared for germline mutation detection, while the supernatant in the centrifuged tubes were collected and stored at -80 ℃ until to be analyzed. The plasma concentration of erlotinib was determined by an on-line column extraction HPLC (Shimadzu Corporation, Kyoto, Japan) coupled with binary peak focusing system that we developed. Chromatography was performed as previously described ([@B20]). The lower limit of quantification was 50 ng/ml for erlotinib.

Genetic Polymorphism Analysis {#s2_3}
-----------------------------

The DNA of the patients for genotyping was extracted from peripheral blood according to the method described previously. The genetic polymorphisms of CYP3A4 rs2242480, CYP3A5 rs 776746, CYP2D6 rs 1065852, CYP1A1 rs1048943, CYP1A2 rs762551, rs2470890, ABCB1 rs1128503, rs1045642, ABCG2 rs2231142, rs2622604, rs7699188 were determined by multiple SNP typing techniques. All samples were analyzed in duplicates and negative controls were included to ensure authenticity of the results.

Data Collection {#s2_4}
---------------

As typical adverse events, the development of skin rash and diarrhea in all patients were monitored in our study, which were rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0). Since the median onset of erlotinib induced skin rash and diarrhea are typical within 1--2 weeks of therapy initiation, and toxicities might be confounded by the number of treatment periods, the grade of erlotinib-induced toxicity was determined during the first 30 days. According to NCI CTCAE v4.0, the severity of skin rash was graded as follows: Grade 1: Papules and/or pustules covering \<10% body surface area (BSA), which may or may not be associated with symptoms of pruritus or tenderness. Grade 2: Papules and/or pustules covering 10%--30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental activities of daily living (ADL). Grade 3: Papules and/or pustules covering \>30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; limiting self care ADL; associated with local superinfection with oral antibiotics indicated. Grade 4: Papules and/or pustules covering any % BSA, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated; life threatening consequences. Grade 5: Death. The severity of diarrhea was graded as follows: Grade 1: Increase of \<4 stools per day over baseline; mild increase in ostomy output compared to baseline. Grade 2: Increase of 4--6 stools per day over baseline; moderate increase in ostomy output compared to baseline. Grade 3: Increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care ADL. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death.

Patient characteristic information, such as sex, height, weight, performance status (PS), disease stage (based on the TNM classification), smoking status, mutational status were obtained from their medical records, and progression free survival (PFS) and AEs were strictly assessed and collected by the members in our study after each follow-up visit. Chest computed tomography (CT) was performed just before treatment, besides, chest CT, a complete blood count, and blood chemistry studies were repeated at least once a month until disease progression. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.1, and response of treatment was defined as complete response (CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm), Partial Response (PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters), Progressive Disease (PD: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study). Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Follow-up was considered as the duration of treatment under erlotinib. PFS was defined as from the date of erlotinib treatment initiation to the date of first documented progression or death. PFS and adverse event were included in the present analysis to correlate with the mean trough level concentration at steady state and pharmacogenetic factors.

Statistical Analysis {#s3}
====================

Data analysis were carried by SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA) in our study and all values were presented as means ± SD. The influence of different genotypes on erlotinib trough levels was analyzed statistically by one-way analysis of variance (ANOVA) with dunnet t test. Fisher\'s exact tests were used to analyze the association between genetic polymorphisms and toxicity. The patient characteristic factors were tested univariately with Cox regression or Kaplane-Meier analysis. The association between SNPs and PFS was univariately tested with Kaplan-Meier analysis. The SNPs were added to the combined clinical characteristic factors to determine the impact of SNPs on PFS. Statistical significance was assumed for p values \< 0.05.

Results {#s4}
=======

Patient Demographics {#s4_1}
--------------------

Patient characteristics at the analysis of the erlotinib plasma concentration were summarized in [**Table 1**](#T1){ref-type="table"}. A total of 87 advanced NSCLC patients were enrolled in our study, 52 (59.8%) male and 35 (40.2%) female, with a median age of 57 years (29-77). The median body weight was 57 kg (37.0--82.5) and the median body surface area was 1.59 m^2^ (1.24--1.92). All the patients in our study were given a fixed dose (150 mg/d) of erlotinib and had good PS, without dose adjustment. The cohort was consisted of 57 non-smokers, 16 patients with smoking history, and 14 currently-smoking patients. All of the patients had major EGFR mutations, with exon 19 deletions (66.7%) and exon 21 L858R (33.3%) respectively.

###### 

Baseline clinical and pathological characteristics of the 87 patients enrolled in the study.

  Patient characteristics   Category/Class     Count (n=24)       Rate (%)
  ------------------------- ------------------ ------------------ ----------
  Age (y), median (range)                      57(29--77)         
  Gender                    Female             52                 59.8
  Male                      35                 40.2               
  Body weight                                  57(37--82.5)       
  BSA (m^2^)                                   1.59(1.24--1.92)   
  Smoking status            Never              57                 65.5
  Former                    16                 18.4               
  Present                   14                 16.1               
  Clinical stage (UICC)     III                24                 27.6
  IV                        63                 72.4               
  ECOG PS                   0                  34                 39.1
  1                         48                 55.2               
  2                         5                  5.7                
  EGFR mutation status      Exon 19 deletion   58                 66.7
  Exon 21 L858R             29                 33.3               

BSA, body surface area; ECOG PS, eastern cooperative oncology group performance status; EGFR, epidermal growth factor receptor.

Genotype Frequencies {#s4_2}
--------------------

The genotype status of the drug-metabolizing enzymes and transporters were determined for all 87 patients. The genotype and allele frequency in the study population were presented in [**Table 2**](#T2){ref-type="table"}.

###### 

Observed genotype and allele frequency of SNPs in the present study (n = 87 patients).

  SNP-ID      Gene     Genotype   n    Identified Frequency %   Allele   Allele frequency %
  ----------- -------- ---------- ---- ------------------------ -------- --------------------
  rs2242480   CYP3A4   C/C        40   45.98                    C        71.26
  C/T         44       50.57      T    28.74                             
  T/T         3        3.45                                              
  rs776746    CYP3A5   C/C        30   34.48                    C        60.92
  C/T         46       52.87      T    39.08                             
  T/T         11       12.65                                             
  rs1065852   CYP2D6   A/A        36   41.38                    A        60.92
  G/A         34       39.08      G    39.08                             
  G/G         17       19.54                                             
  rs1048943   CYP1A1   A/A        11   12.64                    A        27.01
  A/G         25       28.74      G    72.99                             
  G/G         51       58.62                                             
  rs762551    CYP1A2   A/A        38   43.68                    A        65.52
  C/A         38       43.68      C    34.48                             
  C/C         11       12.64                                             
  rs2470890   CYP1A2   C/C        74   85.06                    C        91.95
  C/T         12       13.79      T    8.05                              
  T/T         1        1.15                                              
  rs1128503   ABCB1    A/A        40   45.98                    A        69.54
  G/A         41       47.12      G    30.46                             
  G/G         6        6.90                                              
  rs1045642   ABCB1    G/G        34   39.08                    G        61.49
  G/A         39       44.83      A    38.51                             
  A/A         14       16.09                                             
  rs2231142   ABCG2    G/G        48   55.17                    G        73.56
  G/T         32       36.78      T    26.44                             
  T/T         7        8.05                                              
  rs2622604   ABCG2    C/C        52   59.77                    C        78.16
  C/T         32       36.78      T    21.84                             
  T/T         3        3.45                                              
  rs7699188   ABCG2    G/G        77   88.51                    G        94.25
  G/A         10       11.49      A    5.75                              

Erlotinib Trough Plasma Concentration {#s4_3}
-------------------------------------

Erlotinib trough concentration at steady state was analyzed, and the results were available for 87 patients. The studied NSCLC patients had a wide inter-individual variation in erlotinb trough plasma concentrations, and the mean erlotinib trough plasma concentration was 1354.5 ± 700.3 ng/ml, ranging from 315.6 ng/ml to 4479.83 ng/ml. Trough plasma erlotinib concentration of 8.05% patients were under the target value (500 ng/ml) ([@B12]), which indicates a high potential risk of disease progression and treatment failure.

Influence of Smoking Status on Erlotinib Trough Levels {#s4_4}
------------------------------------------------------

Previous study has reported that erlotinib pharmacokinetic was related to smoking status ([@B11]). In our present study, the smoking status for 14 patients was concurrent smoking. The relationship between smoking status and erlotinib steady state trough concentration was investigated, and the results showed that the mean erlotinib trough plasma concentration for concurrent smokers was significantly lower than those without smoking history (p=0.021). The mean erlotinib trough plasma concentration in concurrent smokers was also lower than former smokers, but without statistical difference ([**Figure 1**](#f1){ref-type="fig"}).

![The relationship between erlotinib steady state trough plasma concentrations and smoking status.](fphar-11-00664-g001){#f1}

Influence of Different Genotypes on Erlotinib Trough Levels {#s4_5}
-----------------------------------------------------------

Effects of genetic polymorphisms of drug-metabolizing enzymes and transporters on erlotinib trough level were investigated in our study. For CYP1A1rs1048943 ([**Figure 2A**](#f2){ref-type="fig"}), the mean steady state erlotinib trough plasma concentration in wild-types (AA) was significantly lower than that of mutant-types (GG) (p=0.007). For CYP1A2rs762551 ([**Figure 2B**](#f2){ref-type="fig"}), rs2470890 ([**Figure 2C**](#f2){ref-type="fig"}), CYP2D6rs1065852 ([**Figure 2D**](#f2){ref-type="fig"}), CYP3A4rs2242480 ([**Figure 2E**](#f2){ref-type="fig"}), CYP3A5rs776746 ([**Figure 2F**](#f2){ref-type="fig"}), no significant difference in the mean steady state erlotinib trough plasma concentration was found in observed genotypes (p \> 0.05). In addition, there was no significant difference among the mean trough concentration of patients stratified based on genotypes of all the drug transporters (ABCB1rs1045642, rs1128503, ABCG2rs2231142, rs2622604, rs7699188) ([**Figure 3**](#f3){ref-type="fig"}).

![The relationship between erlotinib steady state trough plasma concentrations and CYP1A1rs1048943 **(A)**, CYP1A2rs762551**(B)**, rs2470890 **(C)**, CYP2D6rs1065852 **(D)**, CYP3A4rs2242480 **(E)**, CYP3A5rs776746 **(F)**.](fphar-11-00664-g002){#f2}

![The relationship between erlotinib steady state trough plasma concentrations and ABCB1rs1045642 **(A)**, rs1128503 **(B)**, ABCG2rs2231142 **(C)**, rs2622604 **(D)**, rs7699188 **(E)**.](fphar-11-00664-g003){#f3}

Effect of Genetic Polymorphisms on Adverse Reactions {#s4_6}
----------------------------------------------------

As the most frequently observed adverse reactions, the development and severity of skin rash and diarrhea were recorded in our study. As shown in [**Table 3**](#T3){ref-type="table"}, the severity of skin rash was only associated with the polymorphism of rs762551 in CYP1A2 (p=0.029). For diarrhea, the polymorphisms of rs1045642 (p=0.005) and rs1128503 (p=0.007) in ABCB1 and rs776746 (p=0.048) in CYP3A5 was significantly associated with its development, but not the severity grade. For other metabolizing enzymes and transporters, no significant association was observed between polymorphisms and the development and severity of adverse reactions (p \> 0.05).

###### 

Association between genetic polymorphisms and toxicity.

  Gene     Polymorphism   Genotype/diplotype   Skin rash (grade)   P       Diarrhea (grade)   P                        
  -------- -------------- -------------------- ------------------- ------- ------------------ ------- ---- ------- --- -------
  ABCB1    rs1045642      G/G                  7                   20      7                  0.614   27   6       1   0.005
  G/A      8              21                   10                  0.280   25                 14      0    0.154       
  A/A      1              7                    6                           4                  9       1                
  ABCB1    rs1128503      G/G                  2                   3       1                  0.471   4    2       0   0.007
  G/A      8              23                   10                  0.747   33                 7       1    1.000       
  A/A      6              22                   12                          19                 20      1                
  ABCG2    rs2231142      G/G                  9                   26      13                 1.0     33   14      1   0.554
  G/T      6              18                   8                   1.0     18                 13      1    1.000       
  T/T      1              4                    2                           5                  2       0                
  ABCG2    rs2622604      C/C                  10                  26      16                 1.0     33   18      1   1.000
  C/T      6              20                   6                   0.434   21                 10      1    1.000       
  T/T      0              2                    1                           2                  1       0                
  ABCG2    rs7699188      G/G                  15                  43      19                 0.681   49   26      2   1.0
  G/A      1              5                    4                   0.445   7                  3       0    1.0         
  CYP1A1   rs1048943      C/C                  2                   5       4                  0.680   7    4       0   0.687
  C/T      6              15                   4                   0.326   18                 6       1    1.000       
  T/T      8              28                   15                          31                 19      1                
  CYP2D6   rs1065852      G/G                  2                   9       6                  0.822   11   5       1   0.958
  G/A      7              16                   11                  0.200   21                 13      0    0.501       
  A/A      7              23                   6                           24                 11      1                
  CYP3A4   rs2242480      C/C                  5                   27      8                  0.277   21   17      2   0.088
  C/T      11             20                   13                  0.139   32                 12      0    0.275       
  T/T      0              1                    2                           3                  0       0                
  CYP3A5   rs776746       C/C                  3                   19      8                  0.337   14   14      2   0.048
  C/T      11             25                   10                  0.264   34                 12      0    0.217       
  T/T      2              4                    5                           8                  3       0                
  CYP1A2   rs762551       C/C                  0                   7       4                  0.300   5    5       1   0.295
  C/A      8              10                   20                  0.029   24                 13      1    0.241       
  A/A      8              21                   9                           27                 11      0                
  CYP1A2   rs2470890      C/C                  13                  41      20                 0.210   45   17      2   0.634
  C/T      2              7                    3                   1.000   10                 2       0    1.000       
  T/T      1              0                    0                           1                  0       0                

First row, grade 0 versus 1+; second row, grade 0--1 versus 2+; p ≤ 0.05 was considered statistically significant.

Effect of Genetic Polymorphisms on PFS {#s4_7}
--------------------------------------

The relationship between pharmacogenetic factors and PFS was analyzed in our study. In the univariate analysis of PFS, the SNP of rs1048943 in CYP1A1 (AA vs. AG vs. GG, p=0.030) relating to the pharmacodynamics of erlotinib showed an association with survival ([**Table 4**](#T4){ref-type="table"}). As to the multivariate analysis, the characteristic factors of patient body surface area and smoking status (HR 1.042, P=0.008, HR 5.317, P=0.029, respectively) were associated with shorter PFS. When the SNPs of metabolizing enzymes and transporters were added to this model, it can be observed that the CT allele in rs1048943 was associated with longer PFS (HR 0.226, p=0.038).

###### 

Univariate and multivariate analyses of progression-free survival of EGFR mutated NSCLC with 150 mg erlotinib.

                                            N patients                    Univariate KaplaneMeier analyses   Multivariate Cox regression analyses                                   
  ---------------------- ------------------ ----------------------------- ---------------------------------- -------------------------------------- ------- --------------- ------- --
  Clinical factors                                                                                                                                                                  
  Age                                       HR per year increase= 0.979   0.954--1.006                       0.128                                  0.974   0.936--1.012    0.179   
  Body surface area                         HR per year increase= 1.020   1.004--1.036                       0.013                                  1.042   1.011--1.074    0.008   
  Sex                    Male               52                            18                                 13.9--22.1                             0.231   1                       
  Female                 35                 15                            13.6--16.4                                                                0.375   0.113--1.249    0.110   
  Smoking status         Never              57                            19                                 15.7--22.3                             0.027   1                       
  Former                 16                 16                            10.9--22.1                                                                2.529   0.695--9.205    0.159   
  Present                14                 15                            14.1--15.9                                                                5.317   1.184--22.382   0.029   
  Clinical stage         III                24                            24                                 7.8--40.2                              0.204   1                       
  IV                     63                 16                            13.4--18.6                                                                2.004   0.769--5.525    0.155   
  ECOG PS                0                  34                            15                                 11.3--18.7                             0.203   1                       
  1                      48                 18                            15.6--20.4                                                                1.257   0.507--3.115    0.621   
  2                      5                  12                            6.8--17.2                                                                 3.747   0.579--24.244   0.166   
  EGFR mutation status   Exon 19 deletion   58                            18                                 15.1--20.9                             0.197   1                       
  Exon 21 L858R          29                 15                            11.0--19.0                                                                1.318   0.901--1.927    0.155   
  Genetic factors                                                                                                                                                                   
  rs1048943(CYP1A1)      A/A                11                            15                                 8.8--21.2                              0.030   1                       
  A/G                    25                 18                            16.1--20.0                                                                0.226   0.055--0.923    0.038   
  G/G                    51                 18                            13.9--22.1                                                                0.528   0.149--1.869    0.322   
  rs1065852(CYP2D6)      G/G                36                            17                                 13.2--20.8                             0.982   1                       
  G/A                    34                 18                            13.4--22.6                                                                0.804   0.358--1.805    0.596   
  A/A                    17                 15                            9.5--20.5                                                                 1.891   0.756--4.732    0.174   
  rs2242480(CYP3A4)      C/C                40                            17                                 14.6--19.4                             0.802   1                       
  C/T                    44                 15                            6.9--23.1                                                                 1.532   0.541--4.377    0.422   
  T/T                    3                  15                            11.8--18.2                                                                0.742   0.075--7.348    0.799   
  rs776746(CYP3A5)       C/C                30                            18                                 15.6--20.4                             0.831   1                       
  C/T                    46                 15                            13.5--16.5                                                                0.649   0.217--1.934    0.437   
  T/T                    11                 23                            4.1--41.9                                                                 0.313   0.065--1.505    0.147   
  rs762551(CYP1A2)       C/C                11                            15                                 13.3--16.7                             0.097   1                       
  C/A                    38                 18                            14.8--21.2                                                                0.784   0.317--1.937    0.597   
  A/A                    38                 31                                                                                                      0.408   0.131--1.266    1.121   
  rs2470890(CYP1A2)      C/C                74                            17                                 14.4--19.6                             0.783   1                       
  C/T                    12                 17                            12.9--21.1                                                                1.196   0.435--3.287    0.728   
  T/T                    1                  16                                                                                                      0.092   0.004--2.229    0.142   
  rs1045642(ABCB1)       G/G                34                            16                                 13.6--18.4                             0.857   1                       
  G/A                    39                 19                            13.9--24.1                                                                0.935   0.361--2.514    0.923   
  A/A                    14                 17                            12.3--21.7                                                                0.659   0.205--2.123    0.485   
  rs1128503(ABCB1)       G/G                6                             18                                 14.8--21.2                             0.158   1                       
  G/A                    41                 15                            12.4--17.6                                                                0.764   0.346--1.685    0.504   
  A/A                    40                 13                            10.6--15.4                                                                0.920   0.243--3.479    0.903   
  rs2231142(ABCG2)       G/G                48                            16                                 13.2--18.8                             0.598   1                       
  G/T                    32                 20                            17.0--23.0                                                                1.297   0.602--2.794    0.506   
  T/T                    7                  15                                                                                                      0.754   0.131--4.352    0.752   
  rs2622604(ABCG2)       C/C                52                            16                                 13.5--18.5                             0.850   1                       
  C/T                    32                 19                            14.5--23.5                                                                0.908   0.433--1.905    0.799   
  T/T                    3                  23                                                                                                      2.030   0.426--9.662    0.374   
  rs7699188(ABCG2)       G/G                77                            17                                 14.8--19.2                             0.698   1                       
  G/A                    10                 16                            9.3--22.7                                                                 0.730   0.226--2.362    0.559   

Discussion {#s5}
==========

Pharmacokinetics is a potential source of biomarkers and could partially explain the inter-individual variability in erlotinib response in previous studies. In our present study, significant variation of erlotinib steady state trough plasma concentration was observed. The influence of polymorphism of drug metabolizing enzymes and transporters on trough plasma concentration, PFS and adverse events was also observed.

The average erlotinib trough plasma concentration was 1354.5 ± 700.3 ng/ml, ranging from 315.6 ng/ml to 4479.8 ng/ml, with a nearly 14.2 fold variance. Results from our research were consistent with previous studies. Hamada et al. has reported that the mean trough plasma concentration of erlotinib was 1530 ± 780 ng/ml in Japanese NSCLC patient, also with a wide variation (range: 320--3390 ng/ml) ([@B10]). Similarly, trough concentration of erlotinib has also been monitored in the study by Nienke and co-workers, in which the mean trough plasma concentrations for erlotinib was 1010 ng/ml, with a nearly 74.0 fold variance, which was larger than our study ([@B17]). 500 ng/ml was recognized as the targeting trough concentration of erlotinib in the treatment of NSCLC ([@B12]). However, 8.05% of patients have not reached this threshold in our study population, which may lead to a higher risk of disease progression and treatment failure.

The relationship between genetic polymorphisms and erlotinib trough level was also investigated in our study, and the results showed that the mean steady state erlotinib trough plasma concentration in wild-types (AA) of CYP1A1rs1048943 was significantly lower than that of mutant-types (GG) (p=0.007). CYP1A1 is a polymorphic gene which codes for the important phase-I XME aryl hydrocarbon hydroxylase and involves in drug metabolism ([@B14]). In addition, rs1048943 is one of the common genetic mutant sites in CYP1A1, which is strongly associated with susceptibility to various cancers ([@B1]; [@B15]). Previous study showed that the polymorphism of CYP1A1 was associated with the treatment outcome of EGFR-TKI in advanced lung cancer patients ([@B28]). Samyuktha et al. have also reported that a longer survival rate was observed in those patients who carry the mutant-type gene of CYP1A1 in imatinib treated chronic myeloid leukemia patients ([@B16]). The response of imatinib was positively associated with its exposure, which may accounts for the fact that a higher steady state concentration of imatinib was achieved in rs1048943 mutant-type gene patients. Mutant allele GG in rs1048943 is thought to be a risk factor for the development of adverse event, while allele AA in rs1048943 is considered as a risk factor for predicting inadequate clinical efficacy of erlotinib treatment. Therefore, for erlotinib treatment, dose adjustment and drug monitoring are highly suggested in patients who carry allele GG in rs1048943.

The effect of smoking on oral erlotinib pharmacokinetics has been widely studied. In our present study, the steady state trough concentration of erlotinb in concurrent smoking patients was significantly lower than that of those without smoking history, which was consistent with previous studies. [@B11] have reported that smokers required 300mg of erlotinib to achieve similar C~max~ and area under the curve to those of non-smokers only given a 150 mg dose. [@B4] have also reported that steady-state C~trough~ values were about 2-fold lower and the CL/F of erlotinib was about 24% increased in current smokers compared with the values in non-smokers. Investigations into the contribution of CYP1A2 to the metabolism of erlotinib and their induction by cigarette smoking have been widely reported ([@B11]; [@B2]). [@B30] have reported that higher CYP1A2 activity was observed in current smoking NSCLC patients. Efficacy of erlotinib in smoking patients following administration of standard doses diminished possibly due to CYP1A2 mediated increased metabolism of the drug in the liver and tumor tissue ([@B18]). However, the effect of smoking on the activity of CYP1A2 was not investigated in our present study, which could be a limitation. In addition, considering that the exact recommendations for the erlotinib dose modification have not been established yet ([@B13]), traditional fixed dose (150 mg/d) was chosen as the dosage of erlotinib for concurrent smoking patients, not the increased 300 mg/d in our present study.

It is well established that *in vivo* drug-related therapeutic efficacy and toxicity are strongly associated with genetic factors ([@B34]; [@B31]). However, few pharmacogenomic biomarkers were used as predictive factor of toxicity for target therapy. To our knowledge, the incidence rates of skin rash and diarrhea were 81.6% and 35.5%, respectively. Findings from our present study showed that the polymorphism of CYP1A2 was the only statically significant covariate responsible for erlotinib induced skin rash (p = 0.029). As previous study showed, CYP1A2 was considerably involved in erlotinib metabolism ([@B18]) and may be of value in predicting the individual metabolizer status of erlotinib ([@B30]). The polymorphism of CYP1A2 may have a significant influence on the pharmacokinetic of erlotinib, which resulted in the variation of the severity of skin rash in our study. However, Chihiro et al. has pointed out that the SNPs in CYP1A2 have no effect on skin rash of erlotinib in Japanese patients, which was contrary to our study ([@B7]). Other factors additional to CYP1A2 activity may also influence erlotinib induced skin rash. Our present study showed that the occurrence of diarrhea was significantly associated with the tested polymorphisms of the selected genes (ABCB1 and CYP3A5). As a common transporter of erlotinib, ABCB1 was expressed in various organs, especially highly in the entire intestine. Polymorphism of ABCB1 can induce the change in transporter activity, and lower activity leads to higher absorption. Hamada et al. has previously reported that polymorphisms of ABCB1 was prominently related with erlotinib pharmacokinetics and toxicity in NSCLC patients ([@B10]). Ma et al. has also reported that several SNPs in ABCB1 were associated with diarrhea in NSCLC patients treated with gefitinib ([@B21]). Consistent with the studies mentioned above, our present study also observed that SNPs in CYP3A5 were statistically associated with the development of diarrhea. Erlotinib is a substrate of CYP3A5 which is highly and polymorphically expressed ([@B39]; [@B36]). Charles et al. has also reported that polymorphism of CYP3A5 were accompanied with a higher risk of diarrhea in erlotinib treated NSCLC patients ([@B33]). However, the relationship between SNPs in CYP3A5 and diarrhea after administration of erlotinib was rarely reported in other study.

The polymorphisms of CYP1A1 were found to be strongly associated with susceptibility to various cancers ([@B1]; [@B15]). However, little information is known available on the polymorphism of CYP1A1 in relation to the clinical outcomes of NSCLC patients undergoing TKI therapy. Our pharmacogenetic study showed that SNPs in the genes encoding for CYP1A1 were associated with PFS in EGFR sensitive mutation patients who were treated with erlotinib 150 mg/d. The rs1048943 in CYP1A1 were significantly associated with a shorter PFS of patients in the present study. We found that the steady state trough level of erlotinib was significantly increased with this SNP mutation, and previous studies have reported that PFS are positively related with trough concentration in NSCLC patients. Hence, the longer PFS may be induced by the decreased metabolic capacity of CYP1A1 in mutant patients. Nie et al. previously reported that the polymorphism of CYP1A1 has a linkage with clinical outcome of NSCLC patients treated with EGFR-TKI ([@B27]; [@B28]). Previous study also showed that CYP1A1 genetic polymorphism was a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer ([@B40]).

In our present study, SNPs in the pharmacokinetic genes encoding for CYP3A4, CYP2D6 and ABCG2 were not significant associated with erlotinib steady state trough concentration. Furthermore, the same results were also observed for toxicity and survival. Our results were consistent with previous studies ([@B33]; [@B30]; [@B7]), however, it should be pointed out that some results in our study were conflicted with other studies ([@B33]; [@B7]). For the relationship between polymorphisms of CYP3A4, CYP2D6, ABCG2, and survival, a hypothetical explanation would be that most patients had an erlotinib steady state serum level higher than the threshold (500ng/ml) needed for clinical activity, negating any effects that these SNPs may have on the actual serum level above this threshold.

Still, several limitations exist in our study. Firstly, we have only investigated the predictive value of polymorphism of common metabolize enzymes and transporters, the other metabolize enzymes and transporters (such as: organic cation transporters) possibly influencing erlotinib treatment outcomes and toxicity to be explored yet. Secondly, the influence of smoking status on the activity of CYP1A2 was not investigated. Thirdly, the concomitant medication factors with potential PK or pharmacodynamic interactions were not taken into account in our study, which is a limitation of the present study. According to the recorded information of patients in our present study, the incidence rate of concomitantly administered drug was low, which could justify our decision that concomitant medication factors were not considered in the study. However, the effect of concomitant medication factors with potential PK or pharmacodynamic interactions will be considered and investigated in our future study. Last but not the least, a larger sample study is needed to confirm our findings.

Conclusion {#s6}
==========

In summary, our results demonstrated that a large variability of erlotinib steady state trough concentration exists in NSCLC patients. It is also observed that SNPs in CYP1A1 may influence the steady state trough concentration of erlotinib and PFS. The polymorphisms of CYP1A2 plays an important role in the severity of skin rash, and the development of diarrhea was associated with SNPs in ABCB1 and CYP3A5. On the basis of these findings, with the aim of improving treatment efficacy and reducing toxicity, it is highly recommended that TDM (therapeutic drug monitoring) and genotyping should be taken into account in an attempt to further individualize treatment of erlotinib in NSCLC.
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